GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Piotroski F-Score

GenMark Diagnostics (GenMark Diagnostics) Piotroski F-Score : 7 (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicating very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GenMark Diagnostics has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for GenMark Diagnostics's Piotroski F-Score or its related term are showing as below:

GNMK' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of GenMark Diagnostics was 7. The lowest was 2. And the median was 4.


GenMark Diagnostics Piotroski F-Score Historical Data

The historical data trend for GenMark Diagnostics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics Piotroski F-Score Chart

GenMark Diagnostics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 2.00 4.00 7.00

GenMark Diagnostics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 6.00 7.00

Competitive Comparison of GenMark Diagnostics's Piotroski F-Score

For the Medical Devices subindustry, GenMark Diagnostics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMark Diagnostics's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where GenMark Diagnostics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec20) TTM:Last Year (Dec19) TTM:
Net Income was -7.008 + -4.684 + -3.228 + -3.724 = $-18.6 Mil.
Cash Flow from Operations was -7.605 + 7.99 + 6.286 + -0.537 = $6.1 Mil.
Revenue was 38.742 + 40.086 + 42.646 + 50.08 = $171.6 Mil.
Gross Profit was 16.152 + 15.851 + 16.543 + 19.398 = $67.9 Mil.
Average Total Assets from the begining of this year (Dec19)
to the end of this year (Dec20) was
(111.473 + 111.592 + 195.013 + 214.59 + 223.534) / 5 = $171.2404 Mil.
Total Assets at the begining of this year (Dec19) was $111.5 Mil.
Long-Term Debt & Capital Lease Obligation was $84.0 Mil.
Total Current Assets was $173.0 Mil.
Total Current Liabilities was $44.1 Mil.
Net Income was -12.08 + -13.308 + -11.675 + -10.287 = $-47.4 Mil.

Revenue was 21.533 + 18.374 + 20.918 + 27.196 = $88.0 Mil.
Gross Profit was 5.863 + 6.573 + 7.05 + 9.117 = $28.6 Mil.
Average Total Assets from the begining of last year (Dec18)
to the end of last year (Dec19) was
(92.981 + 96.66 + 87.174 + 85.052 + 111.473) / 5 = $94.668 Mil.
Total Assets at the begining of last year (Dec18) was $93.0 Mil.
Long-Term Debt & Capital Lease Obligation was $74.9 Mil.
Total Current Assets was $83.4 Mil.
Total Current Liabilities was $24.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GenMark Diagnostics's current Net Income (TTM) was -18.6. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GenMark Diagnostics's current Cash Flow from Operations (TTM) was 6.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec19)
=-18.644/111.473
=-0.16725126

ROA (Last Year)=Net Income/Total Assets (Dec18)
=-47.35/92.981
=-0.50924382

GenMark Diagnostics's return on assets of this year was -0.16725126. GenMark Diagnostics's return on assets of last year was -0.50924382. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

GenMark Diagnostics's current Net Income (TTM) was -18.6. GenMark Diagnostics's current Cash Flow from Operations (TTM) was 6.1. ==> 6.1 > -18.6 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec19 to Dec20
=84.046/171.2404
=0.49080708

Gearing (Last Year: Dec19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec18 to Dec19
=74.941/94.668
=0.79161913

GenMark Diagnostics's gearing of this year was 0.49080708. GenMark Diagnostics's gearing of last year was 0.79161913. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec20)=Total Current Assets/Total Current Liabilities
=172.962/44.13
=3.91937458

Current Ratio (Last Year: Dec19)=Total Current Assets/Total Current Liabilities
=83.397/24.316
=3.42971706

GenMark Diagnostics's current ratio of this year was 3.91937458. GenMark Diagnostics's current ratio of last year was 3.42971706. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

GenMark Diagnostics's number of shares in issue this year was 71.813. GenMark Diagnostics's number of shares in issue last year was 58.929. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=67.944/171.554
=0.39605022

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=28.603/88.021
=0.32495654

GenMark Diagnostics's gross margin of this year was 0.39605022. GenMark Diagnostics's gross margin of last year was 0.32495654. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec19)
=171.554/111.473
=1.53897356

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec18)
=88.021/92.981
=0.94665577

GenMark Diagnostics's asset turnover of this year was 1.53897356. GenMark Diagnostics's asset turnover of last year was 0.94665577. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GenMark Diagnostics has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

GenMark Diagnostics  (NAS:GNMK) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


GenMark Diagnostics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


GenMark Diagnostics (GenMark Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
5964 La Place Court, Carlsbad, CA, USA, 92008-8829
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.
Executives
Tyler Jensen officer: SVP, Engineering and Tech Dev 5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw officer: VP, Assay Development 5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo officer: VP, Qual, Reg, & Clin Affairs 5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson officer: SVP, Corp. Accounts 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler officer: VP, Human Resources 5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins officer: SVP, Sales 5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director, officer: President & CEO 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier officer: SVP & General Counsel 5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell officer: SVP, Operations 5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff director DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox director 5964 LA PLACE COURT, CARLSBAD CA 92008